Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Jounce Therapeutics, Inc. Initial Public Offering

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

REV Group $275 million IPO

Davis Polk advised REV Group, Inc. on its $275 million initial public offering of 12,500,000 shares of common stock. The shares of common stock are listed on the New York Stock Exchange…

Loxo Oncology, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500 shares of common stock of Loxo Oncology, Inc. The common stock is…

Summit Materials $237 Million Common Stock Offering

Davis Polk advised the joint book-running managers in connection with the approximately $237 million primary offering of 10,000,000 shares of common stock of Summit Materials, Inc. The…

Achaogen, Inc. Follow-On Offering

Davis Polk advised the joint book-running managers in connection with the $100.9 million public offering of common stock of Achaogen, Inc. The common stock is listed onthe NASDAQ Global…

Intesa Sanpaolo consent order issued by New York DFS

Davis Polk advised Intesa Sanpaolo S.p.A. in connection with a consent order issued on December 15, 2016 by the New York State Department of Financial Services. DFS Superintendent Maria T…

Xencor, Inc. Follow-On Offering

Davis Polk advised the sole book-running manager in connection with the $126.5 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global Market…

Kinsale Capital Group, Inc. Follow-On Offering

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $106.3 million follow-on offering of 3,864,000 shares of common stock of…
Back to top